In the Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations

Pharmaceutical Technology

Canister promotes drug stability


StabilOx canister Omega (Multisorb)
"StabilOx" canisters are the newest addition to Multisorb's (Buffalo, NY, http://www.multisorb.com/) series of packaging technologies. Moisture naturally entering the canisters catalyzes a reaction that converts oxygen into iron oxide, thus decreasing the oxygen-related degradation of the drug pro-duct. Adrian Possumato, global manager of pharmaceutical markets for Multisorb, says the product reduces oxygen content to < 1% within 24 h of its initial application into the headspace. The canisters also regulate moisture within packaging and maintain relative humidity at 30–40% for as long as two years. Reducing oxygen content and regulating humidity safeguard product integrity and stability.

The canisters are composed of high-density polyethylene, which requires no stability testing and withstands irradiation sterilization. Their ends are precision-welded and remain sealed under high pressure. The products hold a minimum of 100 cc of oxygen and are designed to be compatible with high-speed packaging systems and dispensing equipment.

Membrane cassettes support high mass transfer


Omega T membrane cassette (Pall Corp.)
Pall Corp. (East Hills, NY, http://www.pall.com/) recently unveiled its "Omega T" series membrane cassettes for biopharmaceutical processing applications involving high protein concentrations. The cassettes feature a new, rigid poly-eurethane encapsulate. The polyeureth-ane protects the screen and membrane inside the encapsulate and reduces overtorquing when the cassettes are placed in the holding device. In addition, the polyeurethane has few extractables and therefore yields high-purity solutions.

The Omega T series units also have a new polypropylene screen. The screen's weave and placement within the cassette increase both processing flux rates and product recovery. The screen also supports high mass transfer of proteins and minimizes the gel layer that normally builds up on the membrane. The cassettes' new exterior design incorporates deep notches and rounded edges and fits more snugly in holding devices than Pall's previous units. The cassettes produce scalable results and can purify recombinant proteins or monoclonal antibodies.

Air dryers save energy


SRC series cycling dryers (Sullair)
The "SRC" series cycling dryers offered by Sullair (Michigan City, IN, http://www.sullair.com/), unlike similar dryers, sense the presence of a partial load. Each dryer's refrigeration circuit incorporates temperature and pressure sensors that shut off the compressor under certain conditions. A glycol base then continues to keep the temperature as low as possible. When the temperature rises, the compressor turns on to cool the glycol down. Britt Shipley, Sullair's manager of contaminant-removal systems, says, "Depending on the load of the package, [the unit] could save 40–60% energy."

The series averages less than 1 psi of pressure drop, which is less than most similar dryers, according to Shipley. The low pressure drop ensures that the units use less power and thus are more energy efficient. The units also save power by using scroll compressors, which have less mass and fewer moving parts than piston compressors.

New Product Announcements may be sent to New Products Editor, Pharmaceutical Technology, 485 Route One South, Building F, First Floor, Iselin, NJ 08830, fax 732.596.0005,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here